Market Context — Why This Technology, Why Now

The global oncology market is rapidly shifting towards targeted therapies and precision medicine, driven by the urgent need for more effective treatments for cancers with high mortality rates. Regulatory bodies are increasingly prioritizing innovations that demonstrate clear clinical benefits in areas of unmet need. This technology, by targeting specific signaling pathways to inhibit pancreatic cancer metastasis, aligns perfectly with these trends, offering a competitive edge where current options are limited.

Key Competitive Advantages
01

Inhibits Intractable Pancreatic Cancer Metastasis: A combination of mTOR and ERK1/2 inhibitors could effectively suppress invasive metastasis of pancreatic cancer cells, offering a new therapeutic strategy to improve patient prognosis beyond current treatments.

02

Unique Therapeutic Approach in a Crowded Field: This technology secured patentability in a highly competitive area with 15 prior art documents, demonstrating strong technical superiority and clear differentiation from existing therapies.

03

Robust IP Foundation and High Reliability: Developed by Kochi University and supported by a leading patent law firm, this patent ensures strong technical credibility and precise claim scope, providing a robust foundation for business development.

Market Opportunity
Oncology (Anti-Cancer Drug Market)
$8B globally (AI est.)
Pancreatic cancer remains a highly fatal disease, with metastasis inhibition being a critical unmet need. The aging global population is driving an increase in cancer patients, intensifying the demand for novel anti-cancer drugs.
Global pharmaceutical companies Oncology biotech firms Cancer research institutions
Personalized Medicine Market
$3.5B globally (AI est.)
This technology targets specific signaling pathways, making it highly suitable for personalized medicine applications where treatments are tailored to individual patient genetic profiles.
Precision medicine developers Diagnostic companies with therapeutic arms Biotech firms specializing in targeted therapies
Biopharmaceutical Market
$20B globally (AI est.)
Biopharmaceuticals, including siRNA technologies, enable targeting previously undruggable pathways with small molecules, maintaining a high growth trajectory in the global market.
Large biopharmaceutical corporations RNA therapeutics developers Gene therapy companies
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a pancreatic cancer cell invasive metastasis inhibitor, comprising specific mTOR inhibitors alone or in combination with ERK1/2 inhibitors, across 5 claims. It successfully demonstrated novelty and inventiveness against 15 prior art documents and two office actions, indicating strong differentiation from existing technologies and high resistance to invalidation.

Competitive White Space

This patent primarily covers specific mTOR/ERK1/2 inhibitor combinations and siRNA for pancreatic cancer metastasis. White space exists in developing novel drug delivery systems for these agents or exploring their efficacy in other cancer types where these pathways are implicated but not explicitly claimed.

Economic Impact
~$0.7M/year estimated revenue potential (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming ~40,000 new pancreatic cancer patients annually in Japan, with ~25% at high risk of invasive metastasis. With a market penetration of 5% after 5 years post-launch and an annual drug price of ~$13.5K (AI est.), annual revenue could reach ~$675K (AI est.). This is an initial estimate, with significant growth potential from increased patient numbers and market penetration.

Speed to Market
4× faster than in-house development
This technology significantly shortens the drug discovery phase by identifying specific combinations of mTOR and ERK1/2 inhibitors and disclosing siRNA sequences. This streamlines the verification of basic mechanisms of action and preclinical data acquisition, accelerating the transition to validation stages compared to developing a new drug from scratch.
Competitive Positioning

X: Treatment Specificity
Y: Development Lead Time Efficiency

Business Models & Applications
💊 Joint Drug Development & Licensing
Enter into joint development agreements for new drugs based on this technology, aiming for revenue through shared R&D costs and future royalties. Collaboration with pharmaceutical companies can accelerate market entry while distributing development risks.
🔬 Companion Diagnostic Development
Develop companion diagnostics to assess pancreatic cancer metastasis risk, based on the inhibition mechanisms identified by this technology. Integrating diagnosis and treatment can advance personalized medicine and create new market value.
🧪 Drug Discovery Platform Utilization
Establish a drug discovery screening platform utilizing this technology to identify novel therapeutic candidates for other intractable cancers or inflammatory diseases. This could enable technology transfer across diverse disease areas and secure new revenue streams.
Adjacent Application Opportunities
🏥 Other Cancer Treatments
Application to Other Intractable Cancers
The metastasis inhibition mechanism demonstrated by this technology could be applied to other intractable advanced cancers, such as gastric, colorectal, or lung cancer, where metastasis is a major challenge. Validating drug efficacy in cancers sharing similar activated signaling pathways could expand the addressable market, potentially impacting millions of patients globally.
🧬 Gene Therapy & RNA Medicine
RNA Therapeutic Platform Development
The siRNA-mediated gene expression control mentioned in this technology could serve as a foundation for developing new RNA therapeutics beyond cancer, for genetic or inflammatory diseases where abnormal gene expression is pathogenic. Combined with advanced RNA delivery technologies, this platform has broad application potential across a multi-billion dollar market.
🧪 Combination Therapy Development
Synergistic Effects with Existing Treatments
Integrating this technology into combination therapies with existing anti-cancer drugs or radiation could enhance treatment efficacy and overcome drug resistance. This approach has the potential to improve outcomes for a significant percentage of patients, estimated to be 20-40% more responsive to treatment, establishing new protocols that surpass current therapeutic limitations.
Integration Roadmap — Estimated 54-Month Deployment
Phase 1: Preclinical Evaluation & Optimization
Duration: 9 months
Re-verify foundational data and conduct detailed efficacy and safety assessments at the preclinical stage. This includes determining appropriate active concentrations and optimal administration routes, establishing non-clinical trial protocols.
Phase 2: Clinical Trial Planning & Initiation
Duration: 18 months
Based on Phase 1 results, develop a clinical trial plan in consultation with regulatory authorities (e.g., PMDA). Following ethical committee approval, initiate first-in-human (Phase I) trials targeting pancreatic cancer patients.
Phase 3: Clinical Development & Regulatory Submission
Duration: 27 months
Based on clinical trial progress and results, if efficacy and safety are confirmed, transition to larger-scale clinical trials (Phase II/III). Concurrently, establish manufacturing processes and gather data for regulatory submission, aiming for early market entry.
Technical Feasibility
This technology combines existing mTOR and ERK1/2 inhibitors with siRNA, which are either already in clinical use or advanced in R&D. This facilitates understanding of action mechanisms and leveraging existing toxicity data, shortening development lead times compared to novel compound discovery. siRNA design based on specific gene sequences is also established, suggesting high reproducibility at the laboratory level.
Success Scenario
Implementing this technology could effectively inhibit invasive metastasis in pancreatic cancer patients whose disease currently progresses rapidly, potentially extending survival and improving quality of life. This would enable healthcare providers to offer more hope to patients and establish market leadership by providing a new treatment option.
Patent Record
APPLICATION NO.
特願2023-109994
REGISTRATION NO.
7502832
FILING DATE
2023年07月04日
GRANT DATE
2024年06月11日
EXPIRATION DATE
2043年07月04日
PATENT HOLDER
国立大学法人高知大学
Examination History
2023年07月06日
出願審査請求書
2023年10月17日
早期審査に関する事情説明書
2023年10月24日
早期審査に関する通知書
2023年10月31日
拒絶理由通知書
2023年12月12日
手続補正書（自発・内容）
2023年12月12日
意見書
2024年02月13日
拒絶理由通知書
2024年04月01日
意見書
2024年04月01日
手続補正書（自発・内容）
2024年05月21日
特許査定